Quality Control
Testing

Method Development
and Validation

Stability Storage
and Testing

GLP and GCP

With over 40 years of analytical chemistry experience, Butterworth Laboratories are a UK based contract laboratory supporting the global pharmaceutical industry. Specialising in the quality control analysis of excipients, API, drug product, packaging and medical devices using recognised international standards, we also develop and validate methods to be used for quality control purposes using a wide range of techniques

Our regular inspections by the MHRA and FDA ensure that the services we provide are of the highest standard required by industry.

Quality ControlTesting

Outsourcing quality control (QC) testing of raw materials, intermediates, active pharmaceutical ingredients (API) and finished products can often prove to be a cost-effective option for many companies. Whether it’s lack of in-house facilities, cost of facility and equipment maintenance, meeting high workloads and short deadlines or simply to provide independent certification, we are able to help.

Our staff are experienced in the use of pharmacopoeial monographs, internationally published standards, client supplied or in-house developed methods.

Method Developmentand Validation

With our wealth of experience in QC testing we are able to bring together, both expert understanding of the technique employed and the practical working knowledge of our analysts to ensure successful method development robust enough for quality control purposes.

Following development of a method, it is vital that its performance is fully validated. Unless the client specifies otherwise, we validate methods to ICH guidelines as required by most regulatory authorities.

Stability Storageand Testing

The nature of Stability Studies makes them ideally suited to Outsourcing. Butterworth undertake testing of samples from Stability Studies for the complete set of study time points, or of just later phase time points.

Stability storage is outsourced to an approved facility, who are also able to handle any Microbiological testing requirements, whilst Photostability Services are handles in-house.

GLP and GCP

Butterworth Laboratories have been a member of the UK Good Laboratory Practice (GLP) Compliance Programme since 1989. As a result, data resulting from the conduct of non-clinical safety assessments is of internationally recognised quality.

Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects.

Our GCP analytical services support the safety and quality assurance of Investigational Medicinal Products (IMP) and subsequently generated clinical sample analysis in compliance with UK and European legislation.

Quality ControlTesting

Outsourcing quality control (QC) testing of raw materials, intermediates, active pharmaceutical ingredients (API) and finished products can often prove to be a cost-effective option for many companies. Whether it’s lack of in-house facilities, cost of facility and equipment maintenance, meeting high workloads and short deadlines or simply to provide independent certification, we are able to help.

Our staff are experienced in the use of pharmacopoeial monographs, internationally published standards, client supplied or in-house developed methods.

Method Developmentand Validation

With our wealth of experience in QC testing we are able to bring together, both expert understanding of the technique employed and the practical working knowledge of our analysts to ensure successful method development robust enough for quality control purposes.


Following development of a method, it is vital that its performance is fully validated. Unless the client specifies otherwise, we validate methods to ICH guidelines as required by most regulatory authorities.

Stability Storageand Testing

The nature of Stability Studies makes them ideally suited to Outsourcing. Butterworth undertake testing of samples from Stability Studies for the complete set of study time points, or of just later phase time points.

Stability storage is outsourced to an approved facility, who are also able to handle any Microbiological testing requirements, whilst Photostability Services are handles in-house.

GLP and GCP

Butterworth Laboratories have been a member of the UK Good Laboratory Practice (GLP) Compliance Programme since 1989. As a result, data resulting from the conduct of non-clinical safety assessments is of internationally recognised quality.

Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects.

Our GCP analytical services support the safety and quality assurance of Investigational Medicinal Products (IMP) and subsequently generated clinical sample analysis in compliance with UK and European legislation.

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue